LOGIN  |  REGISTER
Viking Therapeutics
Assertio

CooperCompanies to Participate in Upcoming Investor Conferences

August 08, 2024 | Last Trade: US$73.51 1.01 -1.36

SAN RAMON, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced its participation in the following upcoming investor conferences:

2024 Wells Fargo Healthcare Conference
Wednesday, September 4, 2024, at 3:45 pm ET
Al White, President & Chief Executive Officer, will represent the Company in a fireside chat

Morgan Stanley Annual Global Healthcare Conference
Thursday, September 5, 2024, at 1:50 pm ET
Al White, President & Chief Executive Officer, will represent the Company in a fireside chat

A webcast of each session will be available to investors and other interested parties by accessing the CooperCompanies’ website at http://investor.coopercos.com.

About CooperCompanies

CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, improving the vision of millions of people every day. CooperSurgical is a leading fertility and women’s health company dedicated to assisting women, babies and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies (“Cooper”) has a workforce of more than 15,000 with products sold in over 130 countries. For more information, please visit www.coopercos.com.

Contact:
Kim Duncan
Vice President, Investor Relations and Risk Management
925-460-3663
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page